stockrow
Saturday 7 November 2026
Export AARD’s income statement to Excel — free account
Aardvark Therapeutics, Inc.
AARD Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −77.1%
Quarter to June 2026, against a year earlier
1.17
0.06
+5.41%
Follow AARD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3 | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (14) | (7) | (21) | (58) | (70) | +61.9% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (14) | (7) | (21) | (58) | (70) | +61.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (3.49) | (1.82) | (5.15) | (2.93) | (3.21) | (5.6%) | ||||||
| Cash flow | — | — | — | — | — | — | (2.71) | (1.47) | (4.53) | (2.76) | (3.18) | +0.6% | ||||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | (0.03) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (2.71) | (1.47) | (4.55) | (2.77) | (3.18) | +0.7% | ||||||
| Book value | — | — | — | — | — | — | 4.11 | (8.79) | 18.04 | 5.43 | 3.42 | +9.8% | ||||||
| Shares, m | — | — | — | — | — | — | 4 | 4 | 4 | 20 | 21 | +71.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (11) | (6) | (18) | (54) | (69) | +72.6% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | 0 | (12.8%) | ||||||
| Free cash flow | — | — | — | — | — | — | (11) | (6) | (18) | (54) | (69) | +72.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 16 | 9 | 69 | 101 | 74 | +85.4% | |||||
| Net debt | — | — | — | — | — | — | (16) | (10) | (74) | (110) | (74) | +89.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 16 | (35) | 72 | 107 | 75 | +88.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (52.82) | (46.77) | (59.16) | (61.06) | (59.2) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (4,986.18) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 22.98 | 46.03 | (221.55) | (66.02) | (221.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 18 | 22 | 40 | — | +49.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Aardvark Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BYSI BeyondSpring Inc. | $26.0M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABVC ABVC BioPharma, Inc. | $25.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RNAZ TransCode Therapeutics Inc. | $25.6M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AARD Aardvark Therapeutics, Inc. | $24.3M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | |
| CVM Cel-Sci Corporation | $24.1M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $23.5M | — (loss-making) | — (loss-making) | −5.30% (below 0%: shrinking) | n/m | −10.91% (below 0%: shrinking) | 56.79% | (78.00%) | Compare |
| NXTC NextCure, Inc. | $23.4M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.0M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IGC IGC Pharma, Inc. | $22.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −45.33% (below 0%: shrinking) | 18.60% | (588.72%) | Compare |
| Median of peers | $23.8M | — | — | +87.78% | — | −6.62% | 37.70% | 0.00% |
Pay and ownership Proxy statement filed 10 July 2026
Ownership
Directors and executive officers, together
17.80%
Entities affiliated with Decheng Capital Global Life Sciences Fund IV, L.P.
17.90%
Jane Wu Lee, M.D.
14.50%
Tien-Li Lee, M.D.
14.50%
Vickers Venture Fund VI Pte. Ltd.
9.40%
Dr. Finian Tan
8.50%
Christopher Ho
7.70%
Entities affiliated with Citadel Advisors LLC
5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement